Keywords: Bayer, Intendis, KYTHERA, BTG, Nycomed, CroFab, DigiFab, ATX-101
Bayer unit gets rights to KYTHERA’s adipolytic dermatology agent in up to $373 million deal; BTG to regain product rights from Nycomed
Article | 31 August 2010
German drugmaker Bayer HealthCare’s (BAY. DE) dermatology business Intendis has entered an agreement with USA-based KYTHERA Biopharmaceuticals to develop ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Is failure to adopt business process management putting the pharma industry at risk?
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
